Skip to main content
SpringerLink
Log in

Microprolactinoma: Medical or surgical treatment as first line approach? The case for medical therapy

  • Opinion
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Davis M.J., Howlett T.A. A survey of the current methods used in the UK to assess pituitary function. J. Royal Soc. Med. 1996, 98: 159–164.

    Google Scholar 

  2. Scanlon M.F., Peters J.R., Salvador J., Richards S.H., John R., Howell S., Williams E.D., Thomas J.P., Hall R. The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinemia due to prolactinomas and non-functional pituitary tumors: relationship to adenoma size at surgery. Clin. Endocrinol. (Oxf.) 1986, 24: 435–446.

    Article  CAS  Google Scholar 

  3. Sawers H.A., Robb O.J., Walmsley D., Strachan F.M., Shaw J., Bevan J.S. An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinemia. Clin. Endocrinol. (Oxf.) 1997, 46: 321–326.

    Article  CAS  Google Scholar 

  4. Greenspan S.L., Neer R.M., Ridgway E.C., Klibanski A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann. Intern. Med. 1986, 104: 777–782.

    Article  CAS  PubMed  Google Scholar 

  5. Testa G., Vegetti W., Motta T., Alagna F., Bianchedi D., Carlucci C., Bianchi M., Parazzini F., Crosignani P.G. Two-year treatment with oral contraceptives in hyperprolactinemic patients contraception. Contraception 1998, 58: 69–73.

    Article  CAS  PubMed  Google Scholar 

  6. Fahy U.M., Foster P.A., Torode H.W., Hartog M., Hull M.G. The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea. J. Gynecol. Endocrinol. 1992, 6: 183–188.

    Article  CAS  Google Scholar 

  7. Corenblum B., Donovan L. The safety of physiological estrogen plus progestin replacement therapy with oral contraceptive therapy in women with pathological hyperprolactinemia. J. Fertil. Steril. 1993, 59: 671–673.

    CAS  Google Scholar 

  8. Bevan J.S., Webster J., Burke C.W., Scanlon M.F. Dopamine agonists and pituitary tumor shrinkage. J. Endocr. Rev. 1992, 13: 220–240.

    Article  CAS  Google Scholar 

  9. Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I., Scanlon M.F., for the Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Engl. J. Med. 1994, 331: 904–909.

    Article  CAS  Google Scholar 

  10. Colao A., Di Sarno A., Sarnacchiaro F., Ferone D., Di Renzo G., Merola B., Annunziato L., Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. Clin. Endocrinol. Metab. 1997, 82: 876–883.

    Article  CAS  Google Scholar 

  11. Duranteau L., Chanson P., Lavionne A., Horlait S., Lubetski J., Kuhn J.M. Effects of new dopaminergic agonist CV 205–502 on plasma PRL levels and tumor size in BRC-resistant prolactinomas. Clin. Endocrinol. (Oxf.) 1991, 34: 25–29.

    Article  CAS  Google Scholar 

  12. Wang C., Lam K.S.L., Ma J.T.C., Chan T., Liu M.Y., Yeung R.T.T. Long-terrn treatment of hyperprolactinemia with bromocriptine: effect of drug withdrawal. Clin. Endocrinol. (Oxf.) 1987, 27: 363–371.

    Article  CAS  Google Scholar 

  13. Tyrrell J.B., Lamborn K.R., Hannegan L.T., Applebury C.B., Wilson C.B. Transsphenoidal microsurgical therapy of prolactinomas: initial outcome and long-term results. Neurosurgery 1999, 44: 254–261.

    Article  CAS  PubMed  Google Scholar 

  14. Molitch M.E. Prolactinoma. In: Melmed S. (Ed.), The Pituitary. Blackwell Scientific, Boston, 1995, p. 443.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Endocrinology, Metabolism and Diabetes, University of Wales College of Medicine, Heath Park, Cardiff, CF4 4XN, Wales, UK

    D. A. Rees, J. S. Davies &  M. F. Scanlon

Authors
  1. D. A. Rees
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. S. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. F. Scanlon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rees, D.A., Davies, J.S. & Scanlon, M.F. Microprolactinoma: Medical or surgical treatment as first line approach? The case for medical therapy. J Endocrinol Invest 23, 122–124 (2000). https://doi.org/10.1007/BF03343691

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343691

Keywords

Search

Navigation